PFBT
SPRY icon

Parkside Financial Bank & Trust’s ARS Pharmaceuticals SPRY Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$643 Buy
+80
New +$767 ﹤0.01% 2491
2025
Q4 		– Sell
-45
Closed -$453 – 2794
2025
Q3 		$453 Hold
45
– – ﹤0.01% 2595
2025
Q2 		$786 Hold
45
– – ﹤0.01% 2338
2025
Q1 		$567 Buy
+45
New +$541 ﹤0.01% 2308

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parkside Financial Bank & Trust's SPRY Position: Q1 2026 in Review

Parkside Financial Bank & Trust opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 80 shares worth $643. The stake represents ﹤0.01% of the portfolio and ranks #2491 among its holdings. This is a return to the name: Parkside Financial Bank & Trust previously reported a position in SPRY as recently as Q3 2025.

Parkside Financial Bank & Trust first reported a position in SPRY in Q1 2025 and has held it in 4 quarters since. The position peaked at $786 in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Parkside Financial Bank & Trust held 80 shares of ARS Pharmaceuticals worth $643 as of Q1 2026.
  • ARS Pharmaceuticals was a new Parkside Financial Bank & Trust position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2491 holding.
  • Parkside Financial Bank & Trust first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Parkside Financial Bank & Trust's ARS Pharmaceuticals position peaked at $786 in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.